Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002

Executive Summary

An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.

You may also be interested in...



Forest Levothroid Misses NDA Approval Deadline; FDA Requests Withdrawal

Forest Labs must cease distribution of its levothyroxine product Levothroid after failing to receive approval of its pending NDA, FDA said in a warning letter posted on the agency's website Aug. 19

Forest Levothroid Misses NDA Approval Deadline; FDA Requests Withdrawal

Forest Labs must cease distribution of its levothyroxine product Levothroid after failing to receive approval of its pending NDA, FDA said in a warning letter posted on the agency's website Aug. 19

King Tigan Suppository sNDA Pushed To 2004 Under Revised FDA Agreement

King has an additional two years to submit an sNDA for Tigan suppositories under an amended agreement with FDA requiring submission by December 2004

Related Content

UsernamePublicRestriction

Register

PS038176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel